Compare Cigna Corp (CI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Neurocrine Biosciences Inc — how do they compare? Cigna Corp trades at $302.09 (market cap $80.25B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: Cigna Corp is far larger — about 4.6× Neurocrine Biosciences Inc's market cap, and Cigna Corp pays a 2.06% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CI | NBIX | |
|---|---|---|
Market Cap | $80.25B | $17.30B |
Sector | Health | Health |
52-Week High | $311.00 | $180.55 |
52-Week Low | $244.41 | $123.10 |
Enterprise Value | $103.35B | $16.39B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
